(Q36094045)

12 August 2017

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response (English)

1 reference

systemic lupus erythematosus

12 August 2017

1 reference

1 reference

1 reference

inferred from title

author

Ronald van Vollenhoven

1

object named as

Ronald F van Vollenhoven

0 references

Ricard Cervera i Segura

3

object named as

Ricard Cervera

1 reference

12 August 2017

2

Michelle A Petri

1 reference

12 August 2017

David A Roth

4

1 reference

12 August 2017

Beulah N Ji

5

1 reference

12 August 2017

Christi S Kleoudis

6

1 reference

12 August 2017

Z John Zhong

7

1 reference

12 August 2017

William Freimuth

8

1 reference

12 August 2017

language of work or name

English

0 references

publication date

15 February 2012

1 reference

Annals of the Rheumatic Diseases

12 August 2017

1 reference

12 August 2017

71

1 reference

12 August 2017

8

1 reference

12 August 2017

1343-1349

1 reference

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Novel evidence-based systemic lupus erythematosus responder index

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

The socioeconomic burden of SLE.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

The role of biomarkers in the assessment of lupus.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Immunologic factors and clinical activity in systemic lupus erythematosus

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Systemic lupus erythematosus.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396451

Accurately describing changes in disease activity in Systemic Lupus Erythematosus

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22337213

12 December 2020

inferred from PubMed ID database lookup

Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22337213

12 December 2020

inferred from PubMed ID database lookup

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22337213

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1136/ANNRHEUMDIS-2011-200937

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22337213

1 reference